Headlines about Oxford Immunotec Global (NASDAQ:OXFD) have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.4304402212754 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of research analysts recently issued reports on OXFD shares. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. BTIG Research set a $21.00 target price on shares of Oxford Immunotec Global and gave the company a “buy” rating in a report on Monday, December 18th. Cowen restated a “buy” rating and set a $15.00 price target on shares of Oxford Immunotec Global in a research report on Monday, January 22nd. Zacks Investment Research upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. Finally, ValuEngine lowered shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $17.80.
Oxford Immunotec Global (OXFD) traded up $0.03 during mid-day trading on Wednesday, hitting $13.18. 39,650 shares of the company’s stock traded hands, compared to its average volume of 219,276. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.37 and a quick ratio of 4.92. Oxford Immunotec Global has a 52-week low of $10.00 and a 52-week high of $19.51. The stock has a market capitalization of $342.03, a P/E ratio of -8.95 and a beta of -0.21.
In other news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 8.11% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.